CAR-T Immunotherapy and Non-small Cell Lung Cancer: Bottleneck and Dawn.
10.3779/j.issn.1009-3419.2020.103.10
- Author:
Li ZHANG
1
;
Heng LI
1
;
Feiyue ZHANG
1
;
Shuting WANG
1
;
Gaofeng LI
1
Author Information
1. Department of Thoracic Surgery, Yunnan Cancer Hospital, Kunming 650118, China.
- Publication Type:Journal Article
- Keywords:
Chimeric antigen receptor modified T cells;
Lung neoplasms;
Target;
Toxicity
- From:
Chinese Journal of Lung Cancer
2020;23(10):916-920
- CountryChina
- Language:Chinese
-
Abstract:
With the deeper understanding of the pathophysiology and pathogenesis of non-small cell lung cancer (NSCLC) which threatens human health, NSCLC treatment has entered a new era. Transition from traditional treatment based on surgery, radiotherapy and chemotherapy to individualized and precise targeted therapy and safer and more effective immunotherapy. Immune checkpoint inhibitor therapy has been approved as a first-line or second-line treatment for advanced NSCLC, and has achieved extraordinary clinical results. Meanwhile, other types of immunotherapy are rarely explored in NSCLC. Chimeric antigen receptor modified T cells (CAR-T cells) perform well in treating several hematological malignancies. However, it is not ideal for treating patients with solid tumors including NSCLC. This review aims to systematically explain the latest progress of CAR-T in the treatment of NSCLC, mainly including: CAR molecular target selection, CAR-T function enhancement and related toxicity management, as well as the difficulties and prospects of CAR-T treatment of NSCLC. It aims to open up new perspectives and unique ideas for the immunotherapy of NSCLC, and contribute to the building of tumor immunotherapy.
.
